A 77-year-old man with known Waldenström macroglobulinemia was examined for unilateral proptosis and periorbital swelling. The patient was found to have an orbital mass involving the lateral wall. Histologic and immunophenotypic matching of the orbital mass to the patient's systemic findings were used to diagnose the orbital mass as a Waldenström macroglobulinemia tumor.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/IOP.0b013e318160dfcc | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A case of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia diagnosed with facial lesions.
J Dermatol
January 2025
Department of Dermatology, Kyushu University School of Medicine, Fukuoka, Japan.
A Rare Case of Chronic Lymphocytic Leukemia Transforming Into Waldenström Macroglobulinemia During Ibrutinib Therapy.
Cureus
December 2024
Endocrinology, State University of New York Downstate Medical Center, Brooklyn, USA.
Chronic lymphocytic leukemia (CLL) can rarely transform into Waldenström macroglobulinemia (WM), posing diagnostic and therapeutic challenges. The diagnosis of WM requires bone marrow infiltration by lymphoplasmacytic cells and the presence of IgM gammopathy. Immunophenotypic markers include FMC7+, CD19+, CD20+, and CD138+.
View Article and Find Full Text PDFBackground: Waldenström's macroglobulinemia (WM) is a very rare disease with an incidence 10times lower than that of multiple myeloma. The incidence of WM is also significantly lower than that of the other CD20+ low-grade lymphomas. The rarity of WM is the reason why registration studies of new drugs used for multiple myeloma or the more common CD20+low-grade lymphomas do not cover WM.
View Article and Find Full Text PDFBackground: Rituximab is already a standard part of the treatment of patients with Waldenström's macroglobulinemia. However, a small proportion of patients develop intolerance to rituximab during administration or the treatment is not very effective. In these patients, we are faced with the question of whether another anti-CD20 monoclonal antibody can be used and what result will be achieved.
View Article and Find Full Text PDFIgM Flare in Anti-MAG Neuropathy Post Rituximab Treatment: A Clinical Case and a Systematic Review of the Literature.
Brain Sci
December 2024
Dipartimento Di Neuroscienze, Università Cattolica del Sacro Cuore, Sede Di Roma, 00168 Rome, Italy.
Background/objectives: Anti-MAG polyneuropathy is a demyelinating peripheral neuropathy associated with IgM monoclonal gammopathies, particularly MGUS (monoclonal gammopathy of undetermined significance) and Waldenström macroglobulinemia. It is characterized by a subacute onset of distal sensory symptoms, with distal motor dysfunction typically appearing only in the later stages of the disease. The condition is caused by the presence of autoantibodies directed against myelin-associated glycoprotein, a structural protein of myelin.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!